Hall Capital Management Co. Inc. Takes Position in Pfizer Inc. (NYSE:PFE)

Hall Capital Management Co. Inc. acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 18,239 shares of the biopharmaceutical company's stock, valued at approximately $484,000.

A number of other large investors have also modified their holdings of the company. Rialto Wealth Management LLC acquired a new position in Pfizer in the 4th quarter worth about $26,000. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC raised its stake in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $28,000. Finally, Noble Wealth Management PBC purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $31,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Trading Up 1.2%

Shares of PFE traded up $0.29 during midday trading on Tuesday, reaching $23.61. The company had a trading volume of 36,119,931 shares, compared to its average volume of 41,080,360. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a 50 day simple moving average of $23.33 and a 200-day simple moving average of $25.13. The stock has a market cap of $134.23 billion, a PE ratio of 16.74, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue was down 7.8% compared to the same quarter last year. During the same period last year, the business earned $0.82 earnings per share. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.29%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

Analysts Set New Price Targets

A number of research firms have weighed in on PFE. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target for the company. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.